Using iCAGES to guide cancer treatment for better outcomes
Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced Cancers
This study is testing if a new tool called iCAGES can help doctors choose better treatments for people with advanced cancers, like lung cancer, to see if it improves their survival and quality of life compared to standard care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT03192501 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of the iCAGES (integrated CAncer GEnome Score) tool in guiding treatment for advanced cancers compared to standard care or IHC-guided therapy. It aims to determine if iCAGES can improve progression-free survival, overall survival, and quality of life for patients with lung cancer and other advanced cancers. The study leverages high-throughput sequencing data to identify gene mutations and recommend targeted therapies based on individual genomic profiles. Patients will receive treatment options that are tailored to their specific genetic mutations, potentially enhancing treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with recurrent or metastatic lung cancer or other advanced cancers who can provide informed consent.
Not a fit: Patients over 70 years old, those with a history of malignant tumors, pregnant or lactating women, and individuals with serious concomitant diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective cancer treatments, improving survival rates and quality of life for patients.
How similar studies have performed: Other studies utilizing precision medicine approaches have shown promise, suggesting that this method could be a meaningful advancement in cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers. * There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals. * The patient is informed consent and signed a written consent. Exclusion Criteria: * Age \> 70 or \<18 years old. * Previous history of malignant tumors. * Pregnant or lactating female patients. * Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.
Where this trial is running
Guangzhou, Guangdong
- The Second Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Zhenfeng Zhang, MD,PhD — Second Affiliated Hospital of Guangzhou Medical University
- Study coordinator: Zhenfeng Zhang, MD,PhD
- Email: zhangzhf@gzhmu.edu.cn
- Phone: +86-020-34153532
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.